DoD Joint Program Committee-2/Military Infectious Diseases Applied Research Award

The summary for the DoD Joint Program Committee-2/Military Infectious Diseases Applied Research Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DoD Joint Program Committee-2/Military Infectious Diseases Applied Research Award: The FY17 JPC-2/MIDRP ARA seeks to fund applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality. These projects are expected to inform and identify which potential health products, approaches, or technologies are best positioned for human testing. The intent of the FY17 JPC-2/MIDRP ARA is to support the following:
• Hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models;
• Refinement of concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products;
• Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo; and
• Completion of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications.
Awards may support studies involving human subjects but not clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Principal Investigators (PIs) seeking support for a clinical trial should apply to the FY17 JPC-2/MIDRP Clinical Studies Award (Funding Opportunity Number: W81XWH-17-DMRDP-MID-CSA).
Awards may not be used to support early-stage, fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind.
Applications must include preliminary and/or published data that is relevant to the award and the proposed research project. Investigators must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale.
Partnering PI Option: The FY17 JPC-2/MIDRP ARA mechanism supports applications that include meaningful and productive collaborations. The Partnering PI Option under this mechanism is structured to accommodate up to three PIs who will each receive a separate award. One partner is identified as the Initiating PI and the other partner(s) as the Partnering PI(s). All investigators should collaborate in the development and submission of the proposed research project. It should be clear that each investigator has a significant level of intellectual input and brings complementary strengths to the project. Multidisciplinary and multi-organizational projects are allowed. If multi-organizational, all participating organizations must be willing to resolve potential intellectual and material property issues and remove any barriers that might interfere with successful completion of the research.